A chemokine receptor as a novel treatment target of age-related macular degeneration,
| Project/Area Number |
23592552
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
YANAGI Yasuo 東京大学, 医学部附属病院, 講師 (90376442)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 加齢黄斑変性 / ケモカイン / CXCR3 / 脈絡膜新生血管 |
|---|
| Research Abstract |
This study investigated the effects of inflammatory cytokine, IP-10, on choroidal neovascularization due to age-related macular degeneration. The results demonstrated that IP-10 is produced in the inflammatory macrophage and retinal pigment epithelial cells and inhibits choroidal neovascularization through its receptor, CXCR3.
This study identified a new treatment target for age-related macular degeneration, a devastating condition leading to legal blindness.
|
Report
(4 results)
Research Products
(2 results)
